Design Therapeutics, Inc. (NASDAQ:DSGN) Director Purchases $66,605.66 in Stock

Design Therapeutics, Inc. (NASDAQ:DSGN) Director John P. Schmid acquired 17,809 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was acquired at an average price of $3.74 per share, for a total transaction of $66,605.66. Following the purchase, the director now directly owns 26,965 shares of the company’s stock, valued at $100,849.10. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Design Therapeutics Stock Performance

DSGN stock opened at $3.91 on Thursday. The firm has a market cap of $220.88 million, a PE ratio of -3.26 and a beta of 1.72. The firm’s fifty day moving average is $2.68 and its 200 day moving average is $2.47. Design Therapeutics, Inc. has a one year low of $1.94 and a one year high of $8.47.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on DSGN. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 price objective on shares of Design Therapeutics in a research note on Wednesday, March 20th. Wedbush reiterated a “neutral” rating and issued a $5.00 price objective on shares of Design Therapeutics in a research note on Wednesday, March 20th. Seven analysts have rated the stock with a hold rating, According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $5.50.

Institutional Trading of Design Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in Design Therapeutics by 1.7% during the third quarter. BlackRock Inc. now owns 3,599,125 shares of the company’s stock valued at $60,177,000 after buying an additional 59,189 shares during the period. RTW Investments LP increased its stake in shares of Design Therapeutics by 60.8% during the third quarter. RTW Investments LP now owns 2,512,986 shares of the company’s stock worth $5,931,000 after purchasing an additional 949,955 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Design Therapeutics by 21.2% during the third quarter. Vanguard Group Inc. now owns 1,551,750 shares of the company’s stock worth $25,946,000 after purchasing an additional 271,706 shares in the last quarter. BML Capital Management LLC purchased a new stake in shares of Design Therapeutics during the fourth quarter worth about $2,728,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of Design Therapeutics by 130.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,023,723 shares of the company’s stock worth $2,713,000 after purchasing an additional 579,225 shares in the last quarter. Institutional investors and hedge funds own 56.64% of the company’s stock.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.